Results 81 to 90 of about 1,481 (180)

Esketamine for treatment resistant depression: a trick of smoke and mirrors? [PDF]

, 2019
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults.
Barbui, C., Gastaldon, C., Ostuzzi, G., Papola, D.   +3 more
core   +2 more sources

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study [PDF]

, 2023
: Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety. It is also indicated for the acute short-term treatment of
Andriola, Ileana, Barlati, Stefano, Bassetti, Roberta, Chiappini, Stefania, Clerici, Massimo, d'Andrea, Giacomo, De Filippis, Sergio, Dell'Osso, Bernardo, Di Nicola, Marco, Martinotti, Giovanni, Pettorruso, Mauro, Sensi, Stefano, Vita, Antonio   +12 more
core   +2 more sources

Dextromethorphan Bupropion Combination Tablet Suicide Attempt by Overdose: A Case Report

Neuropsychopharmacology Reports, Volume 45, Issue 3, September 2025.
Dextromethorphan and bupropion in combination are approved to treat major depressive disorders in adults. This case report describes a patient with a history of treatment‐resistant depression who presented to the emergency department after overdosing on approximately 30 tablets of dextromethorphan‐bupropion 45–105 mg in a suicide attempt.
Daniel Greer, Justina Girgis, John Kashani, Jennifer Atherton   +3 more
wiley   +1 more source

Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression [PDF]

, 2023
Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with
C Courtes, Alan, Jones, Gregory, Machado-Vieira, Rodrigo, Soares, Jair C, Vecera, Courtney M   +4 more
core   +2 more sources

Efficacy of Midazolam in Outpatient Pediatric Dentistry: A Systematic Review

Special Care in Dentistry, Volume 45, Issue 5, September/October 2025.
ABSTRACT Aims The aim of this systematic review was to analyze the efficacy, advantages and adverse effects of midazolam in outpatient pediatric dentistry. Methods This review was carried out in accordance with the PRISMA criteria. A systematic electronic search was conducted through MEDLINE/PubMed, Scopus, and the Cochrane Library databases up to ...
Judit Rabassa‐Blanco, Pau Cahuana‐Bartra, Yndira González‐Chópite, María Dolores Rocha‐Eiroa, Albert Ramírez‐Rámiz, Elias Isaack Mashala, Lluís Brunet‐Llobet, Jaume Miranda‐Rius   +7 more
wiley   +1 more source

Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

Fundamental &Clinical Pharmacology, Volume 39, Issue 4, August 2025.
ABSTRACT In the 1950s–60s, serotonergic psychedelic drugs were studied as potential adjuvants to psychotherapy to treat addiction and alcoholism. However, starting in the 70s, preclinical and clinical studies on psychedelics stopped for decades because legislation controlled its recreational use, citing their hallucinogenic and psychotomimetic effects,
Makiath Adebo, Mathilda Bonnet, Ons Laouej, Celine Defaix, Josephine C. McGowan, Florence Butlen‐Ducuing, Denis J. David, Erwan Poupon, Laurent Tritschler, Alain M. Gardier   +9 more
wiley   +1 more source

HOW CAN WE USE NEUROTRANSMITTERS IN EMOTION AND REWARD SYSTEM TO STUDY DEPRESSION? [PDF]

, 2019
Depression is the most common and widespread psychiatric disorder severely affecting people’s lives at all ages. Factors from social, psychological, and biological aspects can contribute to depression, and many hypotheses are associated with biological ...
Zhang, Pan
core   +2 more sources

Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk

Human Psychopharmacology: Clinical and Experimental, Volume 40, Issue 4, July 2025.
ABSTRACT Objective Treatment‐resistant depression is one of the most significant clinical challenges in psychiatric practice. The primary aim of the present study was to assess the efficacy and tolerability of intranasal esketamine on depressive symptoms in a real‐world outpatient setting.
Maurizio Pompili, Maria Anna Trocchia, Ludovica Longhini, Eva Dispenza, Cristina Di Legge, Salvatore Sarubbi, Denise Erbuto, Isabella Berardelli   +7 more
wiley   +1 more source

Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression

Neuropsychiatric Disease and Treatment, 2022
Joachim Morrens,1 Maju Mathews,2 Vanina Popova,1 Stephane Borentain,2 Benoit Rive,3 Beatriz Gonzalez Martin Moro,4 Carol Jamieson,5 Qiaoyi Zhang2 1Janssen Research & Development, Beerse, Belgium; 2Janssen Global Services, LLC, Titusville, NJ, USA ...
Morrens J, Mathews M, Popova V, Borentain S, Rive B, Gonzalez Martin Moro B, Jamieson C, Zhang Q   +7 more
doaj  

The Nasal–Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases

MedComm, Volume 6, Issue 6, June 2025.
Τhe BBB restricts CNS drug delivery. NBDD bypasses the BBB via olfactory/trigeminal routes, enabling CNS delivery of therapeutic (small molecules, biologics, nucleic acids) for neurodegenerative/psychiatric disorders and brain tumors using advanced NBDD delivery systems (e.g nanocarriers) to enhance targeting and bioavailability.
Yi Qiu, Shiyuan Huang, Li Peng, Li Yang, Guosong Zhang, Tao Liu, Fang Yan, Xi Peng   +7 more
wiley   +1 more source